Clinical trial NCT04785300: ALSENLITE: Senolytics for Alzheimer's Disease
Official title: ALSENLITE: an Open-Label Pilot Study of Senolytics for Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE1
PHASE2
Conditions: Mild Cognitive Impairment
Alzheimer Disease
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-03-05
Enrollment: 20
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.

Detailed description: The underlying processes driving chronic neurodegeneration in Alzheimer's disease (AD) and related neurodegenerative disorders are largely unknown. Aging is the major risk factor for AD. Moreover, individuals with AD suffer from significantly more co-morbid conditions than demographically matched older adults. This study is an open-label pilot study of intermittent administration of the senolytic drug regimen Dasatinib (D) + Quercetin (Q) in symptomatic adults over 55 with clinical diagnosis of probable Alzheimer's Disease and Alzheimer's biomarker positivity by tau-PET.

Eligibility criteria: Inclusion Criteria:

1. Men and women of age 55 years and older at the time of enrollment
2. Clinical diagnosis of symptomatic probable AD (MMSE 26 to 15 or Short Test of Mental Status 31 to 15 inclusive and/or Clinical Dementia Rating Scale/CDR = 0.5 to 2, inclusive)
3. Not on cholinesterase inhibitors or memantine; or if on cholinesterase inhibitors and/or memantine, on a stable dose for at least three months
4. Body Mass Index (BMI) within range of 19 - 50 kg/ m2
5. Participants must be accompanied by a LAR designated to sign informed consent and to provide study partner reported outcomes at all visits
6. Participants must have no plans to travel over the \~3 months between Visits 3 and 14 that interfere with study visits
7. Tau positivity by brain PET imaging
8. Adequate blood counts i.e. platelets \> 50,000 per microliter; HB \> 9/dL, and ANC \> 1000 per microliter
9. Availability and consent from a LAR.

Exclusion Criteria:

1. Unwilling or unable to give informed consent
2. Pregnancy
3. QTc \> 450 msec on baseline ECG
4. MRI contraindications
5. Presence of uncontrolled psychiatric disorder (as per clinical judgment)
6. Presence of uncontrolled systemic lupus erythematosus (as per clinical judgment)
7. Substance or alcohol abuse (current alcohol use \> 3 alcoholic beverage/day or \> 21 per week and as per clinical judgment)
8. Hearing, vision, or motor deficits despite corrective devices (as per clinical judgment)
9. Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6 months
10. Chronic heart failure (as per clinical judgment)
11. Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments (as per clinical judgment)
12. Positive SARS-CoV-2 test within 30 days prior to enrollment
13. AST/ALT \> 2.5x upper limit normal
14. Presence of significant liver disease with total bilirubin \> 2X upper limit or as per clinical judgment
15. Inability to tolerate oral medication (as per clinical judgment)
16. Abnormality in any of the screening laboratory studies (see section 6.21.2) or as per clinical judgment
17. Malabsorption (as per clinical judgment)
18. Known human immunodeficiency virus infection (as per clinical judgment)
19. Known active hepatitis B or C infection
20. Invasive fungal or viral infection (as per clinical judgment)
21. Known hypersensitivity or allergy to D or Q
22. Uncontrolled pleural/pericardial effusions or ascites (as per clinical judgment)
23. New/active invasive cancer except non-melanoma skin cancers
24. Inability to tolerate oral medications (as per clinical judgment)
25. Currently taking AND unable to safely hold any of the medications listed in Appendix 1 during the days IP is administered and for 36 hours after IP administration.
26. Uncontrolled diabetes (defined as HbA1c \> 7% or as per clinical judgment).
27. Gastric bypass/reduction
28. Crohn's disease
29. Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR) (as per clinical judgment)
30. eGFR \< 10 ml/ min/ 1.73 m2
31. Creatinine clearance \< 60 mL/min/1.73 m2
32. Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)
33. On antiplatelet agents (e.g., full dose Aspirin, Clopidogrel etc.). Baby aspirin (81 mg), if absolutely necessary from cardiac perspective, will be allowed
34. Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial

Involvement of special vulnerable populations: We will not involve special vulnerable populations, such as fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations except for patients with dementia. Therefore, availability and consent from a LAR is an inclusion criterion.

Primary outcomes:
measure: Safety and Tolerability
timeFrame: 11 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Vijay K. Ramanan, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Guerrero A, De Strooper B, Arancibia-Carcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer's disease. Trends Neurosci. 2021 Sep;44(9):714-727. doi: 10.1016/j.tins.2021.06.007. Epub 2021 Aug 5.